Market Overview

Bank of America Reiterates Buy Rating on Aegerion Pharmaceuticals Following ACC Meeting

Related AEGR
Activist Discloses 5.7% Stake In Aegerion Pharmaceuticals
10 Biotech Stories You Might've Missed This Week

In a report published Monday, Bank of America reiterated its Buy rating and $42.00 price target on Aegerion Pharmaceuticals (NASDAQ: AEGR).

Bank of America noted, “Familial hypercholesterolemia (FH) was a highly visible topic at this weekend's American College of Cardiology (ACC) meeting in San Francisco. AEGR's recently approved Juxtapid (lomitapide) and its ultra-orphan indication homozygous FH (HoFH) were discussed in depth at a lipid lowering therapeutics symposium. Physicians from the US and abroad noted the need for therapies beyond apheresis to treat HoFH. A presenter from the Netherlands described the greater use of genetic testing in that country that indicated the assumed prevalence of one in one million for HoFH could be outdated and may be closer to one in 250K (equates to 1,200 HoFH and 1.2mn HeFH in the US).”

Aegerion Pharmaceuticals closed on Friday at $36.90.

Latest Ratings for AEGR

Oct 2014NeedhamDowngradesBuyHold
Oct 2014JefferiesDowngradesBuyHold
Oct 2014JP MorganDowngradesOverweightNeutral

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Reiteration Analyst Ratings


Related Articles (AEGR)

Around the Web, We're Loving...

Get Benzinga's Newsletters